Back to News
Market Impact: 0.4
Alaunos Therapeutics Announces Acquisition of Velaris Therapeutics
Source: globenewswire.com
M&A & RestructuringPrivate Markets & VentureHealthcare & Biotech
The company is acquiring Velaris and completed a concurrent oversubscribed $350 million private placement. It says the combination positions it to deliver multiple proof-of-concept datasets in pulmonary arterial hypertension; the article provides no valuation, timeline, or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
More News
- How tech icon Meg Whitman is already leaving her mark on grocery giant Albertsons
- J&J's 6% slide on an imperfect quarter is a gift to prospective buyers
- UnitedHealth Group tops estimates, hikes profit outlook as insurer manages high medical costs
- Talos Energy 10% owner sells $106.8m in shares
- AI companion startup Character.ai files for Chapter 11 bankruptcy, citing costs and litigation
- SpaceX IPO Helps Fuel $100 Billion Space Boom
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AlphaSense Pricing: What Public Contract Data Shows in 2026
- Eli Lilly Q4 2025 Earnings: Revenue Surges 43% as Mounjaro and Zepbound Dominate the GLP-1 Market